



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/1/19
LAST REVIEW DATE: 2/21/19
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NATPARA® (parathyroid hormone) subcutaneous injection

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as “**Description**” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as “**Criteria**” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

NATPARA® (parathyroid hormone) subcutaneous injection (cont.)

Criteria:

NATPARA IS AVAILABLE ONLY THROUGH A RESTRICTED PROGRAM UNDER A RISK EVALUATION AND MITIGATION STRATEGY (REMS) CALLED THE NATPARA REMS PROGRAM.

- **Criteria for initial therapy:** Natpara (parathyroid hormone) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in or is in consultation with an Endocrinologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of hypoparathyroidism with hypocalcemia that is not controlled with use of calcium and vitamin D
 4. Natpara will be used as adjunct therapy to control hypocalcemia
 5. **ALL** of the following baseline tests have been completed before initiation of treatment with continued monitoring as clinically appropriate:
 - 25-hydroxyvitamin D is greater than 20 ng/mL
 - Serum calcium greater than 7.5 mg/dL
 - Serum albumin
 6. No evidence of hypocalcemia or hypercalcemia (serum calcium or corrected serum calcium is within the normal range)
 7. Natpara is not being used to treat hypoparathyroidism caused by calcium-sensing receptor variants
 8. Natpara is not being used in individuals with acute post-surgical hypoparathyroidism
 9. Natpara is not being used concurrently with a bisphosphonate (Actonel, Fosamax, others)
 10. Natpara is not being used concurrently with Forteo (teriparatide) or Tymlos (abaloparatide) or Prolia (denosumab)

Initial approval duration: 3 months

- **Criteria for continuation of coverage (renewal request):** Natpara (parathyroid hormone) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in or is in consultation with an Endocrinologist
 2. Individual's condition responded while on
 - Response is defined as:
 - Achieved and maintains **ONE** of the following:

NATPARA® (parathyroid hormone) subcutaneous injection (cont.)

- Total serum calcium (albumin-corrected) is within the lower half of the normal range (i.e., between 8-9 mg/dL) without the need for active forms of vitamin D and with use of calcium supplementation sufficient to meet the individual's daily requirements
 - At least a 50% reduction from baseline in the dose of active vitamin D
 - At least a 50% reduction from baseline in the dose of oral calcium supplementation
 - No evidence of disease progression
3. Individual has been adherent with the medication
 4. Natpara is not being used concurrently with a bisphosphonate (Actonel, Fosamax, others)
 5. Natpara is not being used concurrently with Forteo (teriparatide) or Tymlos (abaloparatide) or Prolia (denosumab)
 6. Individual has not developed any significant unacceptable level 4 adverse drug effects that may exclude continued use
 - Significant adverse effect such as:
 - Severe hypercalcemia
 - Severe hypocalcemia
 - Hypercalciuria (urine calcium > 300mg/24 hours or > 7.5 mmol/24 hours)
 - Osteosarcoma

Renewal duration: 12 months

- Natpara (parathyroid hormone) for all other indications not previously listed or if above criteria not met is considered **experimental or investigational** based upon:
1. Lack of final approval from the Food and Drug Administration, and
 2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and
 3. Insufficient evidence to support improvement of the net health outcome, and
 4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, and
 5. Insufficient evidence to support improvement outside the investigational setting.

These indications include, *but are not limited to*:

- Treatment with dosing or frequency outside the FDA-approved dosing and frequency

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/1/19
LAST REVIEW DATE: 2/21/19
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NATPARA® (parathyroid hormone) subcutaneous injection (cont.)

Description:

Natpara, parathyroid hormone, is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in individuals with hypoparathyroidism. Because of the potential risk of osteosarcoma, Natpara is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone.

Parathyroid hormone raises serum calcium by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption (by converting 25-OH vitamin D to 1, 25-OH₂ vitamin D) and by increasing bone turnover which releases calcium into the circulation.

The dose of Natpara should be individualized based on total serum calcium (albumin-corrected) and 24-hour urinary calcium excretion. When using Natpara, adjust the dose of active vitamin D or calcium supplement or both based on serum calcium value and clinical assessment for signs and symptoms of hypocalcemia or hypercalcemia.

The maintenance of Natpara should be the lowest dose that achieves a total serum calcium (albumin-corrected) within the lower half of the normal total serum calcium range (approximately 8 and 9 mg/dL), without the need for active forms of vitamin D and with use of calcium supplementation sufficient to meet daily requirements. Monitor serum calcium and 24-hour urinary calcium per standard of care once a maintenance dose is achieved

The dose of Natpara is increased if serum calcium cannot be maintained above 8 mg/d without an active form of vitamin D and/or oral calcium supplementation. Doses are decreased if total serum calcium is repeatedly above 9 mg/dL after the active form of vitamin D has been discontinued and calcium supplement has been decreased to a dose sufficient to meet daily requirements. Abrupt interruption or discontinuation of Natpara can result in severe hypocalcemia.

Natpara was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. Natpara was not studied in patients with acute post-surgical hypoparathyroidism.

Use of Natpara is subject to a Risk Evaluation and Mitigation Strategies (REMS) program that requires provider, patient, and dispensing pharmacy be enrolled into the program. Use of Natpara is associated with a higher potential risk of osteosarcoma that may be dependent on dose and treatment duration. Only providers and Pharmacies enrolled into the REMS may prescribe and dispense the drug, respectively, to individuals who are also in the program. A REMS program attempts to manage known or potentially serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) for some drugs to ensure that the benefits of a drug outweigh its risks

Definitions:

Adult: Age 18 years and older

Albumin-corrected serum calcium [cCa, mg/dL]:

Individual's serum calcium (mg/dL) + 0.8 (4.0 – individual's serum albumin [g/dL])



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/1/19
LAST REVIEW DATE: 2/21/19
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NATPARA® (parathyroid hormone) subcutaneous injection (cont.)

25 hydroxy-vitamin D levels:

20-50 ng/mL (50-125 nmol/L)

Resources:

Natpara (parathyroid hormone) product information accessed 12-17-18 at DailyMed:
<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d11fba31-0a6c-11e3-8ffd-0800200c9a66>

UpToDate: Hypoparathyroidism. Current through Nov 2018. https://www.uptodate-com.mwu.idm.oclc.org/contents/hypoparathyroidism?search=hypoparathyroidism&source=search_result&selecte dTitle=1~141&usage_type=default&display_rank=1

UpToDate: Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment. Current through Nov 2018. https://www-uptodate-com.mwu.idm.oclc.org/contents/vitamin-d-deficiency-in-adults-definition-clinical-manifestations-and-treatment?topicRef=99737&source=see_link

Pharmacy Prior Authorization Request Form

6. Is there any additional information the prescribing provider feels is important to this review? Please specify below.
For example, explain the negative impact on medical condition, safety issue, reason formulary agent is not suitable to a specific medical condition, expected adverse clinical outcome from use of formulary agent, or reason different dosage form or dose is needed.

Signature affirms that information given on this form is true and accurate and reflects office notes

Prescribing Provider's Signature: _____ Date: _____

Please note: Some medications may require completion of a drug-specific request form.

Incomplete forms or forms without the chart notes will be returned.

Office notes, labs, and medical testing relevant to the request that show medical justification are required.